Your browser doesn't support javascript.
loading
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.
Linn, Swe M; Novitzky-Basso, Igor; Abduljalil, Omar; Pasic, Ivan; Lam, Wilson; Law, Arjun; Michelis, Fotios V; Gerbitz, Armin; Viswabandya, Auro; Lipton, Jeffrey; Kumar, Rajat; Mattsson, Jonas; Kim, Dennis D H.
Afiliação
  • Linn SM; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Canada.
  • Novitzky-Basso I; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Canada.
  • Abduljalil O; Faculty of Medicine, Department of Medicine, University of Toronto, Canada.
  • Pasic I; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Canada.
  • Lam W; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Canada.
  • Law A; Faculty of Medicine, Department of Medicine, University of Toronto, Canada.
  • Michelis FV; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Canada.
  • Gerbitz A; Faculty of Medicine, Department of Medicine, University of Toronto, Canada.
  • Viswabandya A; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Canada.
  • Lipton J; Faculty of Medicine, Department of Medicine, University of Toronto, Canada.
  • Kumar R; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Canada.
  • Mattsson J; Faculty of Medicine, Department of Medicine, University of Toronto, Canada.
  • Kim DDH; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Canada.
Hematol Oncol Stem Cell Ther ; 17(1): 60-71, 2023 Jul 20.
Article em En | MEDLINE | ID: mdl-37581458
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Idioma: En Ano de publicação: 2023 Tipo de documento: Article